Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells
- PMID: 7858500
- DOI: 10.3109/10428199409051674
Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells
Abstract
The induction of apoptosis following topoisomerase inhibitors proceeds in at least three distinct steps: (1) induction of cleavable complexes (potentially lethal damage), (2) topoisomerase-induced DNA damage, and (3) a presently unknown sequence of events that must either lead to cell cycle arrest (G2-block, differentiation) or apoptosis. DNA degradation provides a convenient way to quantify apoptosis in HL-60 cells. Extensive apoptosis can be induced rapidly in undifferentiated HL-60 cells without prevention by cycloheximide or actinomycin D. Therefore, HL-60 cells appear to express constitutively the apoptotic machinery that may be kept under control of a yet unknown repressor. The absence of the tumor suppressor p53 and the presence of bcl-2 are in contrast with the sensitivity of these cells to apoptosis. Agents that modify chromatin structure (zinc, poly[ADPribose] inhibitors, spermine) can block DNA fragmentation without affecting cell survival. By contrast macrophage-like differentiation by phorbol esters suppresses apoptosis without affecting topoisomerase-induced DNA damage. Better understanding of the apoptotic regulation in the widely used and characterized HL-60 cell line should allow the identification of new mechanisms and parameters of cellular sensitivity and resistance to the cytotoxic activity of anticancer agents.
Similar articles
-
Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors.Exp Cell Res. 1993 Aug;207(2):388-97. doi: 10.1006/excr.1993.1206. Exp Cell Res. 1993. PMID: 7688316
-
Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.Cancer Res. 1988 Dec 1;48(23):6625-33. Cancer Res. 1988. PMID: 2846155
-
[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors].Bull Cancer. 1996 Mar;83(3):205-12. Bull Cancer. 1996. PMID: 8695922 French.
-
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.Adv Pharmacol. 1994;29B:127-43. doi: 10.1016/s1054-3589(08)61135-7. Adv Pharmacol. 1994. PMID: 8996605 Review.
-
Features of apoptotic cells measured by flow cytometry.Cytometry. 1992;13(8):795-808. doi: 10.1002/cyto.990130802. Cytometry. 1992. PMID: 1333943 Review.
Cited by
-
Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice.World J Gastroenterol. 2000 Apr;6(2):210-215. doi: 10.3748/wjg.v6.i2.210. World J Gastroenterol. 2000. PMID: 11819558 Free PMC article.
-
An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.PLoS One. 2011;6(8):e23597. doi: 10.1371/journal.pone.0023597. Epub 2011 Aug 10. PLoS One. 2011. PMID: 21853156 Free PMC article.
-
Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis.EMBO J. 1996 Mar 1;15(5):1012-20. EMBO J. 1996. PMID: 8605870 Free PMC article.
-
Type IA Topoisomerases as Targets for Infectious Disease Treatments.Microorganisms. 2021 Jan 1;9(1):86. doi: 10.3390/microorganisms9010086. Microorganisms. 2021. PMID: 33401386 Free PMC article. Review.
-
In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer.J Inflamm Res. 2021 Sep 22;14:4901-4913. doi: 10.2147/JIR.S329401. eCollection 2021. J Inflamm Res. 2021. PMID: 34588796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
